Drug Profile

TAS 303

Alternative Names: [¹⁴C] TAS 303; TAS-303

Latest Information Update: 14 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Taiho Pharmaceutical
Class Acetates; Benzene derivatives; Esters; Ethers; Piperidines; Small molecules; Urologics
Mechanism of Action Adrenergic uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

22 Feb 2023 Taiho Pharmaceutical completes a phase I mass-balance trial in Healthy volunteers in Japan (PO) (NCT05621447)
22 Dec 2021 Taiho Pharmaceutical completes a phase II trial in Stress urinary incontinence in Japan (PO) (NCT04512053)
04 Sep 2020 Taiho Pharmaceutical initiates a phase II trial in Stress urinary incontinence in Japan (PO) (NCT04512053)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com